Chemours Co

Chemours maintains a highly leveraged capital structure with total liabilities of $7.05 billion against total equity of $215 million, resulting in a debt-to-equity ratio of 19.07. The company holds $563 million in cash and equivalents against $4.1 billion in long-term debt, creating a net cash deficit. Liquidity is supported by a current ratio of 1.82, and management asserts sufficient liquidity through operating cash flows, unrestricted cash, and revolving credit facility availability to settle liabilities through at least May 2027. However, operating cash flow was negative $44 million in Q1 2026, and free cash flow was negative $93 million, indicating reliance on external financing or cash reserves to fund operations and capital expenditures of $49 million.

Profitability remains under pressure with a net loss of $29 million in Q1 2026, yielding a negative return on equity of -1.80% and a negative return on assets of -0.05%. Gross profit was $212 million on revenue of $1.38 billion, implying a gross margin of approximately 15.4%. The valuation snapshot shows a price-to-book ratio of 24.57, reflecting the thin equity base relative to the market capitalization of $4.13 billion. The enterprise value-to-revenue multiple stands at 1.32, suggesting the market prices the company based on revenue scale rather than current earnings power.

Chemours Co (CC) has entered the analysis scope with no prior basis for delta computation, marking the first comprehensive review of the ticker. This initial assessment establishes a baseline for future monitoring, as there are no recorded material changes or cross-source signals to indicate recent operational shifts or market events. The absence of historical comparison data means that current metrics serve as the foundational reference point for the company's financial and operational status. The most notable activity within the available data involves significant modifications to institutional holdings, flagged as major severity events. Specifically, investor ID 931 adjusted its position, with records showing a shift between holding 200 shares and 3,873 shares as of March 31, 2026. These changes, detected in mid-July 2026, reflect substantial volatility in this specific holder's stake, although the net direction is ambiguous due to conflicting before/after states in the signal logs. Similarly, investor ID 587 executed major modifications to its Chemours position during the same period. Data indicates a dramatic swing in share count, alternating between 107 shares and 52,288 shares as of March 31, 2026. These adjustments, detected between July 5 and July 8, 2026, represent a significant reallocation of capital by this holder, highlighting active trading or reporting corrections within the company's shareholder base. Despite these holder-level fluctuations, the broader corporate profile remains static in terms of analyst and index coverage. Chemours currently reports zero analyst counts, zero index memberships, and zero officer counts in the provided dataset, while maintaining a top holder count of 34. This lack of external analyst or index presence suggests that the recent holder changes are isolated to specific institutional investors rather than reflecting a broader shift in market sentiment or corporate governance structure.

Chemours generated positive free cash flow of $51 million in FY2025, reversing the prior year's significant negative cash flow position.

The company maintained a current ratio of 1.78, indicating sufficient short-term assets to cover immediate liabilities as of late 2025.

Revenue showed slight stability with FY2025 total revenue reaching $5.8 billion, nearly matching the previous fiscal year's performance.

Chemours reported a net loss of $386 million in FY2025, a severe deterioration from the $86 million net income in FY2024.

The debt-to-equity ratio stands at an extreme 19.07, placing the company in the bottom quartile of its chemical cohort.

The company faces medium-level liquidity and dilution risks, highlighting potential vulnerabilities in its capital structure and cash management.

Revenue $1.38B; Net margin -2.1%.

• ▍Revenue $1.38B
• ▍Net margin -2.1%

Revenue $4.48B; Net margin -7.3%.

• ▍Revenue $4.48B
• ▍Net margin -7.3%

Revenue $2.98B; Net margin -12.9%.

• ▍Revenue $2.98B
• ▍Net margin -12.9%

Revenue $5.81B; Net margin -6.6%.

• ▍Revenue $5.81B
• ▍Net margin -6.6%

Revenue $1.50B; Net margin -22.7%.

• ▍Revenue $1.50B
• ▍Net margin -22.7%

Revenue $1.61B; Net margin -23.5%.

• ▍Revenue $1.61B
• ▍Net margin -23.5%

Revenue $1.37B; Net margin -0.4%.

• ▍Revenue $1.37B
• ▍Net margin -0.4%

Revenue $5.78B; Net margin 1.5%.

• ▍Revenue $5.78B
• ▍Net margin 1.5%